Patents Examined by P. L. Touzeau
-
Patent number: 5830857Abstract: A method is described for the therapeutic use of brain-derived neurotrophic factor (BDNF) to treat epilepsy.Type: GrantFiled: July 14, 1995Date of Patent: November 3, 1998Assignee: Amgen Inc.Inventors: Josette Fran.cedilla.oise Carnahan, Antoine Depaulis, Paul Feltz, Yves Larmet, Christian Marescaux, Hiroyuki Nawa
-
Patent number: 5763401Abstract: A stable albumin-free Recombinant Factor VIII (rFVIII) formulation in lyophilized form having both crystalline and amorphous components and comprising, when reconstituted with water, about 65 to 400 mM glycine, up to 50 mM histidine, 15 to 60 mM sucrose, up to 50 mM NaCl, up to 5 mM CaCl.sub.2 and 50 to 1500 IU/ml of rFVIII. A very preferred formulation comprises upon reconstitution with water about 290 mM glycine, 20 mM histidine, 30 mM sucrose, 30 mM NaCl, 2.5 mM CaCl.sub.2 and 50 to 1500 IU/ml of rFVIII. The residual water content of the lyophilized preparation is about 1 to 3% by weight, preferably about 1% by weight.Type: GrantFiled: July 12, 1996Date of Patent: June 9, 1998Assignee: Bayer CorporationInventor: Rajiv Nayar
-
Patent number: 5733871Abstract: Intravenous administration and pharmaceutically acceptable compositions of neurotrophic factors for treating neuronal damage in the central nervous system of individuals in need of such treatment are disclosed. The neuronal damage associated with ischemia, hypoxia, or neurodegeneration may result from stroke or cardiac arrest. This invention provides for the intravenous administration of neurotrophic factors such as bFGF, aFGF, NGF, CNTF, BDNF, NT3, NT4, IGF-I and IGF-II.Type: GrantFiled: March 16, 1995Date of Patent: March 31, 1998Assignee: The General Hospital CorporationInventors: Brian J. Alps, Christine Mary Brown, Franklin D. Collins, Caroline J. Emmett, Michael Spedding, Deborah Russell, Seth P. Finklestein, Michael A. Moskowitz, Roger Lewis Whiting
-
Patent number: 5731287Abstract: A process for the long term modification and regulation of lipid metaboli-generally to reduce obesity, insulin resistance, and hyperinsulinemia (the three hallmarks of Type II diabetes)--by injections into the bloodstream of a vertebrate, animal or human, of prolactin, or both prolactin and a glucocorticosteroid. The injections are made over a limited period at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases (or increases) in body fat deposits result by treatment of an obese species (lean species) on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean members (or obese members) of a similar species. Insulin resistance, and hyperinsulinemia can also be controlled in humans on a long term basis by treatment corresponding to that of the treatment for obesity.Type: GrantFiled: May 26, 1995Date of Patent: March 24, 1998Assignee: Louisiana State University and Agricultural and Mechanical CollegeInventors: Albert H. Meier, Anthony H. Cincotta
-
Patent number: 5723441Abstract: Treatment with IGF/IGFBP-3 complex increases renal tubular mass and potentiates and/or stimulates kidney function in subjects suffering from acute and chronic renal failure or insufficiency resulting from such disorders as glomerulonephritis, glomerulosclerosis, interstitial nephritis, acute tubular necrosis due to ischemia and drug-induced toxicity, diabetic and autoimmune nephropathies and renal dysfunction due to acute and chronic rejection episodes in post-transplantation patients.Type: GrantFiled: August 31, 1995Date of Patent: March 3, 1998Assignee: Celtrix Pharmaceuticals, Inc.Inventors: Howard R. Higley, Christopher A. Maack
-
Patent number: 5691306Abstract: The present invention provides compositions and methods for increasing secretory protein production. In another aspect, the present invention provides compositions for use in methods of treating and diagnosing protein trafficking disorders. These methods generally involve the alteration of calnexin activity to increase protein secretion or retention.Type: GrantFiled: August 25, 1994Date of Patent: November 25, 1997Assignee: National Research Council of CanadaInventors: John J. M. Bergeron, David Y. Thomas, Ikuo Wada
-
Patent number: 5688766Abstract: The present invention relates to oral and edible compositions intended to provide an anticaries benefit. The primary active ingredient in these compositions is a protein selected from the group consisting of cystatin S, cystatin SA, cystatin SN and mixtures thereof which are salivary proteins. Also included are fragments of the proteins which may be used in place of the total proteins.Type: GrantFiled: August 23, 1995Date of Patent: November 18, 1997Inventor: George Joe Revis
-
Patent number: 5688769Abstract: A method for inhibiting ovarian steroidogenesis in women comprising administering to women an ovarian steroidogenesis inhibitorilly effective amound of D Ser (tbu).sup.6 des Gly NH.sub.2 .sup.10 LH-RH ethylamide.Type: GrantFiled: November 30, 1994Date of Patent: November 18, 1997Assignee: Roussel UclafInventors: Fernand Labrie, Jean-Pierre Raynaud
-
Patent number: 5686415Abstract: Colon epithelial cells are stimulated to multiply, grow and mature by contacting them in vivo with peptides derived from the EGF-like domain of proteins of the NDF/heregulin family.Type: GrantFiled: December 5, 1996Date of Patent: November 11, 1997Assignee: Amgen Inc.Inventors: Josette Fran.cedilla.oise Carnahan, Shinichi Hara, Hsieng Sen Lu, John Philip Mayer, Steven Kiyoshi Yoshinaga
-
Patent number: 5641749Abstract: The present invention relates generally to methods for treating injury or degeneration of retinal ganglion cells by administering glial cell line-derived neurotrophic factor (GDNF). The invention relates specifically to methods for treating optic nerve injury or degeneration associated with glaucoma.Type: GrantFiled: November 29, 1995Date of Patent: June 24, 1997Assignee: Amgen Inc.Inventors: Qiao Yan, Jean-Claude Louis
-
Patent number: 5635479Abstract: A process for treating a gynecological malignancy in a host which comprises administering to the host at least one biologically active amphiphilic peptide or protein. The peptide or protein may be administered intralesionally, intravenously, or intraperitoneally, whereby the peptide or protein may inhibit, prevent, or destroy the growth of the gynecological malignancy, such as an ovarian cancer, uterine cancer, or cervical cancer.Type: GrantFiled: May 2, 1995Date of Patent: June 3, 1997Assignee: Magainin Pharmaceuticals Inc.Inventors: Leonard S. Jacob, W. Lee Maloy, Margaret A. Baker
-
Patent number: 5532217Abstract: There is disclosed a process for the mineralization of collagen fibers whereby collagen fibers formed from collagen are contacted with a solution of calcium and phosphate ions under conditions to effect nucleation and in-vitro growth of mineral crystals within and on the surface of the collagen fibers to form intact collagen fibers with subfibrillar substructure and wherein preparations of such mineralized collagen fibers are used in bone replacement therapy as well as to induce repair in bony defects.Type: GrantFiled: September 7, 1995Date of Patent: July 2, 1996Inventors: Frederick H. Silver, David Christiansen
-
Patent number: 5416074Abstract: The protein materials of the invention are essentially those obtained through reaction of a concentrated aqueous solution of type I and/or type III collagens and elastin or elastin peptides having a molecular weight above about 10,000, which can be dissolved in water. Preferred ratios of collagen reactants to elastin reactants in the process of the invention are in the range 1:10. The materials of the invention are obtained through solubilization of elastin.Type: GrantFiled: March 20, 1992Date of Patent: May 16, 1995Assignee: Institut National de la Sante et de la Recherche MedicaleInventors: Michel Rabaud, Francoise Lefebvre
-
Patent number: 5204094Abstract: A method of treating pneumothoraxes in warm-blooded animals comprising administering to warm-blooded animals an amount of polypeptide having human interleukin 2 activity sufficient to treat pneumothoraxes.Type: GrantFiled: January 16, 1992Date of Patent: April 20, 1993Assignee: Roussel UclafInventors: Maud Brandely, Christian Boutin
-
Patent number: 5198213Abstract: Whey derived from ordinary milk includes a bottom fraction including lactose and minerals, a middle fraction including lower molecular weight proteins, and a top fraction including higher molecular weight proteins. The top whey fraction includes a measurable but low level concentration of immunologically active immunoglobulin plus other pathogen specific antibodies. The whey is ultrafiltered through one or more different process steps to yield a filtered product having a concentration of immunologically active immunoglobulin of at least about seven percent of total solids. The filtered product is periodically tested to verify its activity to a specified microbe. The filtered product is orally administered in a therapeutically effective dose to an animal to treat a disease.Type: GrantFiled: October 16, 1991Date of Patent: March 30, 1993Assignee: Protein Technology, Inc.Inventors: Gerald H. Stott, David O. Lucas
-
Patent number: 5175253Abstract: Novel short peptides of up to about 20 amino acid residues are disclosed that bind to the SEC receptor. These novel peptides preferably are pentapeptides which are synthetic analogs of a pentapeptide domain in the carboxy-terminal fragment of .alpha..sub.1 -antitrypsin (amino acids 370-374, Phe-Val-Phe-Leu-Met [SEQ ID NO:2]). A preferred binding peptide is Phe-Val-Ala-Leu-Met [SEQ ID NO;6].Type: GrantFiled: April 24, 1991Date of Patent: December 29, 1992Assignee: Washington UniversityInventors: Robert J. Fallon, Joseph W. Bulock, Steven P. Adams, David H. Perlmutter
-
Patent number: 5164487Abstract: Method of manufacturing an intravenously tolerable immunoglobulin-G preparation that is free of aggregates, vasoactive substances and proteolytic enzymes and accordingly appropriate for all types of patients, especially immunosuppressed patients, from a starting material that contains immunoglobulin G but from which the coagulation factors have been removed. The starting material is treated with 0.4 to 1.5% by volume of octanoic acid and then chromatographed, especially on an ion or cation exchanger or hydrophobic matrix.Type: GrantFiled: March 15, 1991Date of Patent: November 17, 1992Assignee: Biotest Pharma GmbHInventors: Norbert Kothe, Dieter Rudnick, Detlef Piechaczek, Herwald Klein, Detlef Rohm, Michael Kloft
-
Patent number: 5128322Abstract: There is provided a novel therapeutic agent for use in the prevention or treatment of hemorrhage associated with acute nonlymphocytic leukemia or its therapy, as well as a method of prevention or treatment of hemorrhage associated with acute nonlymphocytic leukemia or its therapy with the therapeutic agent, and a method of prevention or treatment of hemorrhage associated with acute nonlymphocytic leukemia or its therapy with the therapeutic agent in combination with one or more other agents indicated for the treatment of acute nonlymphocytic leukemia.Type: GrantFiled: June 25, 1991Date of Patent: July 7, 1992Assignee: Imperial Chemical Industries plcInventor: Mitchell Glass
-
Patent number: 5099005Abstract: Methods of enhancing immunoglobulin fragment yield of immunoglobulins exhibiting anomalous bands when analyzed by SDS-PAGE techniques are provided. Such yield enhancement methods include the steps of desialylating the immunoglobulin; and fragmenting the immunoglobulin produced in the desialylating step. A particular advantage of the present invention is that the fragmention step can be carried out in the presence of cysteine without decreasing the quality of the immunoglobulin fragment product. Methods of enhancing the molecular weight homogeneity of immunoglobulin or fragmented immunoglobulin exhibiting anomalous bands when analyzed by SDS-PAGE techniques are also discussed. These methods include the steps of desialylating the immunoglobulin or fragmented immunoglobulin and purifying the desialylated product.Type: GrantFiled: September 28, 1990Date of Patent: March 24, 1992Assignee: NeoRx CorporationInventors: Everett J. Nichols, Robert F. McIntyre